Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein


Inhibiting the ability of HIV-1, the virus that causes AIDS, to infect cells is one approach to both prevention and treatment of HIV. Scientists at the NIAID Vaccine Research Center have isolated and characterized neutralizing antibodies (VRC01, 02, 03, and 07) that bind to the CD4 binding site of HIV-1 envelope glycoprotein gp120. These human monoclonal antibodies can potentially be used as a therapeutic to: (1) treat an HIV infection, (2) decrease and prevent HIV-transmission from mother to infant, and (3) be effectively combined with anti-retroviral drug therapy. Additionally, the antibodies can be used for detection of HIV-1 infection in biological samples, including body fluids; and tissues from biopsies, autopsies, and pathology specimens.

VRC01 has been tested in several phase I clinical trials for safety and pharmacokinetics in infants, adults, and HIV-positive adults. VRC01 is currently being evaluated in a phase II clinical trial for prevention of HIV-1 acquisition.

Potential Commercial Applications: Competitive Advantages:
  • Monoclonal antibodies to treat and/or diagnose HIV and/or AIDS
  • Immunoassays and kits
 
  • Monoclonal neutralizing antibodies prevent viral entry into cells
  • Monoclonal neutralizing antibodies can be used for vaccine design and to develop diagnostics for HIV-1


Inventors:

John Mascola (NIAID)  ➽ more inventions...

Richard Wyatt (NIAID)  ➽ more inventions...

Xueling Wu (NIAID)  ➽ more inventions...

Yuxing Li (NIAID)  ➽ more inventions...

Carl-Magnus Hogerkorp (NIAID)  ➽ more inventions...

Mario Roederer (NIAID)  ➽ more inventions...

Zhi-yong Yang (NIAID)  ➽ more inventions...

Gary Nabel (NIAID)  ➽ more inventions...

Peter Kwong (NIAID)  ➽ more inventions...

Tongqing Zhou (NIAID)  ➽ more inventions...

Mark Connors (NIAID)  ➽ more inventions...

Gilad Ofek (NIAID)  ➽ more inventions...

Jiang Zhu (NIAID)  ➽ more inventions...

Lawrence Shapiro (NIAID)  ➽ more inventions...

Yongping Yang (NIAID)  ➽ more inventions...

William Schief

Rebecca Rudicell (NIAID)  ➽ more inventions...

Young Do Kwon (NIAID)  ➽ more inventions...

Ivelin Georgiev (NIAID)  ➽ more inventions...

Baoshan Zhang (NIAID)  ➽ more inventions...

Gwo-yu Chauang (NIAID)  ➽ more inventions...

Wei Shi (NIAID)  ➽ more inventions...

Gwo-Yu Chuang (NIAID)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 9,175,070 issued 2015-11-03
U.S. Pat: 8,637,036 issued 2014-01-28
U.S. Pat: 9,738,703 issued 2017-08-22
U.S. Pat: 10,035,845 issued 2018-07-31
U.S. Pat: 9,695,230 issued 2017-07-04
U.S. Pat: 10,035,844 issued 2018-07-31
US Application No. 13/498,125
US Application No. 13/429,286
US Application No. 14/864,705
US Application No. 15/661,867
US Application No. 61/385,531
US Application No. 13/429,279
US Application No. 61/568,520
US Application No. 61/613,431
US Application No. 61/698,452
PCT Application No. PCT/US2012/068827
US Application No. 14/363,740
US Application No. 15/612,846
US Application No. 16/044,083
Various international patent applications may also be available.

Publications:
Nabel G, et al. PMID 26041300
Nabel G, et al. PMID 25142607
Wu X, et al. PMID 21325411
Zhou T, et al. PMID 20616231

Licensing Contact:
Vince Contreras, Ph.D.
Email: vincent.contreras@nih.gov
Phone: 240-669-2823

OTT Reference No: E-300-2009-0
Updated: Jun 22, 2018